Aller au contenu principal
En direct Manifestation « contre le racisme anti-blancs » à Angers : en dépit de l’interdiction, les néofascistes déroulent leur haine
635 nouveau 1 angles 8,911 dossiers
Dimanche 22 novembre 2026 0
Traduit par NobuAI Les articles non francophones sont affichés en français quand une traduction NobuAI est disponible. Traductions NobuAI disponibles.
FDA scientists opposed Trump administration’s move to ease peptide access
Article · Lu chez The Guardian · il y a 3 semaines

Les scientifiques de la FDA se sont opposés à la décision de l’administration Trump de faciliter l’accès aux peptides

Traduit par NobuAI Article original en EN affiché en français.
Source The Guardian GB · EN
Gauche Associatif
Crédibilité de la source 85/100
Aperçu Résumé multi-sources à venir si d'autres couvertures rejoignent cette histoire.

Les efforts visant à assouplir les règles sur les médicaments peptidiques non prouvés, favorisés par RFK Jr, se sont heurtés à une forte résistance de la part des scientifiques de l'agence. Le projet visant à donner aux Américains un accès plus facile aux médi...

Texte intégral

Lire l'article complet dans GrimbaNews

805 mots

A plan to give people in the United States easier access to unproven peptide drugs favored by the US health secretary, Robert F Kennedy Jr, was opposed by most Food and Drug Administration scientific staff members, who had limited input in drafting the policy, according to six people familiar with its development.

The document posted online on Wednesday by Kennedy’s Department of Health and Human Services (HHS) covers a handful of injectable peptides promoted within the wellness industry for building muscle, healing injuries and boosting energy.

The effort on peptides, driven almost entirely by HHS, faced overwhelming pushback among FDA drug staffers who warned it could undermine the agency’s longstanding mission of keeping unproven health products off the US market, according to the people familiar with its development.

‘It’s a peptide wild west’: how RFK Jr is clearing way for a market of untested drugsRead more

The people spoke to the Associated Press on the condition of anonymity to discuss confidential government deliberations. An HHS spokesperson did not immediately respond to a request for comment.

The policy directs the FDA not to take action against specialty pharmacies that sell a half-dozen wellness peptides, including BPC-157, TB-500 and KPV. Under FDA rules, those chemicals would otherwise be considered illegal drugs because they have not gone through the agency’s rigorous review process for safety and effectiveness.

Some peptides occur naturally in the human body, where they trigger hormones needed for growth, metabolism and healing. Drug companies have brought several to market as medications, including mainstay treatments for diabetes and weight loss. But the chemicals subject to the new policy haven’t been approved as safe and effective by the FDA.

Kennedy has called himself a “big fan” of peptides and recently described using BPC-157 to treat a muscle injury.

The new document represents a step back from HHS’s original plans, according to two of the people who discussed its development.

HHS officials initially wanted the FDA to draft an official regulation that would add BPC-157 and other peptides to a list of drug substances deemed safe for use by compounding pharmacies, specialty businesses that make customized medications.

FDA officials warned that the agency’s scientific staffers had major safety concerns and would not support a regulation deeming them safe. HHS officials moved to a different approach that directs the FDA not to enforce its rules against pharmacies that compound the substances.

FDA staffers ultimately provided technical assistance in drafting the HHS plan, including guardrails intended to improve safety, such as requiring pharmacies to use peptide ingredients from FDA-registered factories.

Decisions over compounding have long rested with the FDA, not HHS.

Kennedy has said that US compounding pharmacies must be allowed to sell peptides because Americans are turning to “gray market” products imported from China and other countries.

Decisions about regulating peptides and compounding pharmacies have almost always come from the FDA, which has an office dedicated to protecting US consumers from unsafe or poor-quality compounded drugs.

skip past newsletter promotionFree newsletter |Around 2-3 times a day

Sign up to Breaking News US

Get the most important news as it breaks

after newsletter promotion

The issue of compounding safety became a greater focus for the FDA after a deadly outbreak of fungal meningitis in 2012 was linked to contaminated injections from a Massachusetts compounding pharmacy. Once a niche business, compounding has grown into a multibillion-dollar industry, providing customized medications to doctors, clinics and hospitals.

It’s extremely rare for HHS to take the lead in drafting policies over the compounding industry, former FDA officials said. However, federal law technically gives HHS authority over essentially all drug regulations, which are then delegated to the FDA.

The FDA has warned Americans about safety risks of unproven peptides

Many in the US who are using peptides today do not deal with a doctor or a pharmacy to get the injections, but often order vials online sold by chemical manufacturers based in China. Peptide sellers often try to skirt US regulations by labeling their products as “for research use only” because the FDA does not regulate research chemicals.

In 2023, the FDA added more than a dozen peptides, including BPC-157 and TB-500, to its list of substances that should not be compounded due to risks of allergic reactions, kidney damage and tumor growth.

At a meeting in July, FDA staffers reiterated that more than half a dozen peptides brought forward for reconsideration remained unproven in terms of safety and effectiveness.

The new policy from HHS avoids a direct confrontation with FDA staffers because it only directs the FDA not to enforce certain rules.

HHS ultimately included several safety measures suggested by FDA staffers, according to two of the people. Besides sourcing ingredients from FDA-registered facilities, compounders will be directed to collect information on side effects for safety analysis and verify the chemical identity of peptides.

Source originale : The Guardian ↗

Partager cette histoire

Envoyez le dossier, pas seulement un titre isolé.

Twitter Bluesky
Partager :
System Admin

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont marqués *

Your experience on this site will be improved by allowing cookies.